Dinesh Khanna, MD
Rheumatology · Ann Arbor, MINPI 1508822503
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $951,682 of the $1,228,636 with a category attached, or 77.5%. It is spread thinly across 37 manufacturers, the largest accounting for just 15.9%. 2025 is the largest year on record at $310,606, 2.1 times the $148,416 reported in 2019. Among rheumatology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 573 payments — averaging $2144.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$195K
- Astrazeneca UK Limited$146K
- CSL Behring$131K
- Boehringer Ingelheim International GmbH$117K
- Argenx US, Inc.$116K
- E.r. Squibb & Sons, L.L.C.$47K
- plus $477K from 31 others
Across 64 payments — averaging $418,659 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$25.7M
- Pfizer$355K
- E.r. Squibb & Sons, L.L.C.$221K
- Seagen Inc.$206K
- Bayer$172K
- Boehringer Ingelheim International GmbH$44K
- plus $130K from 13 others
What the payments were for
- Royalty or licence$10,0151%
- Consulting fees$951,68277%
- Speaking & faculty fees$87,1747%
- Travel & lodging$169,82314%
- Food & beverage$9,9411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,228,636 in reported general payments places this provider in the 95th percentile of 195 rheumatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Actemra ActpenTocilizumab | 17 | $108,722 |
| Mycophenolate Mofetil | 83 | $19,202 |
| Sildenafil Citrate | 19 | $6,417 |
| Hydroxychloroquine Sulfate | 16 | $372 |
| Famotidine | 11 | $162 |
| Gabapentin | 16 | $155 |
| Prednisone | 26 | $90 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Ann Arbor
- Elena SchiopuAnn Arbor$180K
- Daniel ClauwAnn Arbor$102K
- Katherine ChakrabartiAnn Arbor$82K
- Puja KhannaAnn Arbor$78K
- Joanne KahlenbergAnn Arbor$74K
- John VargaAnn Arbor$64K
- Samardeep GuptaAnn Arbor$58K
- Jason KnightAnn Arbor$38K
- Sheeja FrancisAnn Arbor$23K
- Inocencio CuestaAnn Arbor$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.